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We previously demonstrated that blocking hepatocyte growth factor (HGF) receptor/c-Met signaling
inhibited arthritis and articular bone destruction in mouse models of rheumatoid arthritis (RA). In
the present study, we investigated the role of c-Met signaling in osteoblast differentiation using the
C2C12 myoblast cell line derived from murine satellite cells and the MC3T3-E1 murine pre-os-
teoblast cell line. Osteoblast differentiation was induced by treatment with bone morphogenetic
protein (BMP)-2 or osteoblast-inducer reagent in the presence or absence of either HGF antagonist
(NK4) or c-Met inhibitor (SU11274). Osteoblast differentiation was conﬁrmed by Runx2 expression,
and alkaline phosphatase (ALP) and osteocalcin production by the cells. Production of ALP, osteocal-
cin and HGF was veriﬁed by enzyme-linked immunosorbent assay. Runx2 expression was conﬁrmed
by reverse transcription-PCR analysis. The phosphorylation status of ERK1/2, AKT, and Smads was
determined by Western blot analysis. Both NK4 and SU11274 enhanced Runx2 expression, and
ALP and osteocalcin production but suppressed HGF production in BMP-2-stimulated C2C12 cells.
SU11274 also enhanced ALP and osteocalcin production in osteoblast-inducer reagent-stimulated
MC3T3-E1 cells. SU11274 inhibited ERK1/2 and AKT phosphorylation in HGF-stimulated C2C12 cells.
This result suggested that ERK and AKT were functional downstream of the c-Met signaling path-
way. However, both mitogen-activated protein kinase/ERK kinase (MEK) and phosphatidylinositol
3-kinase (PI3K) inhibitor suppressed osteocalcin and HGF production in BMP-2-stimulated C2C12
cells. Furthermore, SU11274, MEK, and PI3K inhibitor suppressed Smad phosphorylation in
BMP-2-stimulated C2C12 cells. These results indicate that although the c-Met-MEK-ERK-Smad and
c-Met-PI3K-AKT-Smad signaling pathways positively regulate osteoblast differentiation, c-Met
signaling negatively regulates osteoblast differentiation, independent of the MEK-ERK-Smad and
PI3K-AKT-Smad pathways. Therefore, blocking c-Met signaling might serve as a therapeutic strategy
for the repair of destructed bone in patients with RA.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with rheumatoid arthritis (RA) often have severe sys-
temic bone loss and increased risk of fracture due to increasedbone resorption, and decreased bone formation [1]. Receptor
activator of nuclear factor kappa-B ligand (RANKL), secreted by
synovial tissues, plays a critical role in osteoclastogenesis [2].
Synovial ﬁbroblasts from patients with RA express RANKL [3].
RANKL is also expressed by T cells in the synovial tissues of RA
patients [4]. Bone formation requires coordination between osteo-
blasts and osteoclasts. This coordination is mediated by multiple
growth factors and cytokines [5]. The bone morphogenetic proteins
(BMPs) are members of the transforming growth factor (TGF)-b
superfamily, and they play a central role in bone formation [6].
BMPs are expressed preferentially in mesenchymal tissues preﬁg-
uring the future skeleton, developing bones, and differentiated
chondrocytes and osteoblasts [7]. Tumor necrosis factor (TNF)-a
342 S. Shibasaki et al. / FEBS Open Bio 5 (2015) 341–347is highly expressed in patients with RA, and it inhibits bone forma-
tion by affecting major osteoblast regulatory pathways [8,9].
Angiogenic growth factors such as ﬁbroblast growth factor
(FGF)-2 and FGF-4 [10,11], and vascular endothelial growth factor
(VEGF) [12] act synergistically with BMP-2 to promote osteoblast
differentiation. Conversely, hepatocyte growth factor (HGF), which
is an angiogenic growth factor, has an inhibitory effect on osteo-
blast differentiation [13,14]. HGF enhances angiogenesis, and
HGF receptor (c-Met)-mediated signaling events appear to induce
synovial cell proliferations in RA. NK4 is a fragment of HGF that
was constructed by proteolytic digestion, and it consists of 447
residues with a molecular weight of approximately 55–69 kDa.
NK4 comprises the N-terminal hairpin and subsequent four-kringle
domains of HGF, but lacks the 16 amino acids at the C-terminus of
the a-chain and the whole b-chain. NK4 functions as an HGF antag-
onist by competitively binding to c-Met [15,16]. We previously
demonstrated that the HGF antagonist, NK4, inhibits arthritis by
suppressing angiogenesis and inﬂammatory cytokine production
by CD4+ T cells in SKG mice, an animal model of RA. We also
demonstrated that articular bone destruction is inhibited by NK4
treatment [17]. In the present study, we investigated the role of
c-Met signaling in osteoblast differentiation using C2C12 myo-
blasts, a cell line derived from murine satellite cells and the
MC3T3-E1 murine pre-osteoblast cell line [18,19].
2. Materials and methods
2.1. Cell cultures
The C2C12 murine myoblast cell line and the MC3T3-E1 murine
pre-osteoblast cell line were purchased from the American Type
Culture Collection (Manassas, VA, USA) [18,19]. C2C12 or MC3T3-
E1 cells were grown in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM; Sigma, St. Louis, MO, USA) containing 10% fetal
bovine serum (FBS) and antibiotics (100 units/mL penicillin and
100 lg/mL streptomycin) at 37 C under a humid atmosphere of
95% air/5% CO2.2.2. Alkaline phosphatase (ALP) and osteocalcin assays
The ALP and osteocalcin assays were performed as described
previously [20]. Brieﬂy, C2C12 or MC3T3-E1 cells were seeded in
24-well tissue culture plates at a density of 1  105/mL/well.
C2C12 cells were cultured with BMP-2 (300 ng/mL; R&D systems,
Minneapolis, MN, USA) and MC3T3-E1 cells were cultured with the
osteoblast-inducer reagent (2% b-glycerophosphate, 0.2% hydrocor-
tisone, and 1% ascorbic acid-2-phosphate; TaKaRa, Shiga, Japan) and
ALP or osteocalcin activities in the culture supernatants were deter-
mined after 7 or 10 days of culture, respectively. C2C12 cells were
preincubated for 72 h in the presence of either mitogen-activated
protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)
(MEK) 1/2 inhibitor (PD98059) or phosphatidylinositol 3 kinase
(PI3 K) inhibitor (Ly294002; Promega, Madison, WI, USA). After rig-
orous washing, the cells were stimulated with BMP-2 (300 ng/mL)
for an additional 10 days, and theosteocalcin activities in the culture
supernatants were determined. The concentrations of ALP or
osteocalcin in the culture supernatants were determined using a
mouse ALP (Bio Vision Research Products Mountain View, CA, USA)
or osteocalcin (Biomedical Technologies, Inc., Stoughton, MA, USA)
enzyme-linked immunosorbent assay (ELISA) kit, respectively.2.3. HGF ELISA
The concentrations of HGF in the culture media were assayed
using a mouse HGF ELISA kit (RayBio, Norcross, GA, USA).2.4. Western blot analysis
Western blot analysis was performed as described previously
[21]. Brieﬂy, C2C12 cellswere seeded in12-well tissue cultureplates
at an initial density of 2  106 cells/mL/well, and then stimulated
with BMP-2 (300 ng/mL). After 10 min of stimulation, Western blot
analysis was performed. Brieﬂy, the cells were lysed in radio
-immunoprecipitation assay (RIPA) lysis buffer (Santa Cruz
Biotechnology, CA, USA), and the protein content was determined
using Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA),
with bovine serum albumin as the standard. Each sample (20 lg)
was resolved on a 10 % polyacrylamide gel under denaturing condi-
tions and then transferred to a 0.45-lm nitrocellulose membrane.
After blocking overnight at 4 Cwith 5% nonfatmilk in Tris-buffered
saline containing 0.01% Tween 20 (Santa Cruz Biotechnology), the
membranes were incubated overnight at 4 C with anti-phospho-
ERK 1/2 antibody (1:1000 dilution in phosphate-buffered saline
[PBS]; Santa Cruz Biotechnology), anti-phospho-AKT antibody
(1:1000 dilution in PBS; Santa Cruz Biotechnology), anti-phospho-
smad1/5/8 antibody (1:1000 dilution in PBS; Santa Cruz
Biotechnology), or mouse anti-b-actin antibody (Cell Signaling
Technology, Beverly, MA, USA). After washing the membranes with
Tris-buffered saline containing 0.05% Tween 20 (washing buffer),
horseradish peroxidase (HRP)-conjugated secondary antibody
(1:1000 dilution in PBS; Santa Cruz Biotechnology) was added,
followed by incubation for 45 min. After further washing, color
was developed using luminol reagent (Santa Cruz Biotechnology),
and the HRP activity of the blots was analyzed using a LAS1000
imager (Fuji ﬁlm, Tokyo, Japan).2.5. Quantitative reverse transcription-polymerase chain reaction
(RT-PCR)
Runx2 mRNA expression was determined by using quantitative
RT-PCR. C2C12 cells were seeded in 24-well tissue culture plates at
a density of 1  106 cells/mL/well. The cells were stimulated with
BMP-2 (300 ng/mL). After 24 h of culture, RNA was extracted and
quantitative RT-PCR was performed using a TaKaRa PCR kit
(Takara). Primers used for Runx2 and b-actin RT-PCR assay were
purchased from Applied Biosystems (Tokyo, Japan). Data represent
the relative expression levels of Runx2 mRNA to control b-actin
mRNA.
2.6. Statistical analysis
The results are expressed as the mean ± standard error (SE). The
signiﬁcance of the differences between the experimental results
and the control values was determined by Student’s t-test. p values
less than 0.05 were considered signiﬁcant.3. Results
3.1. HGF antagonist (NK4) and c-Met inhibitor (SU11274) enhance
osteoblast differentiation by C2C12 cells
Using C2C12 myoblasts, we examined the effect of NK4 on
osteoblast differentiation. First, we examined the effect of NK4
on the ALP activity of BMP-2-stimulated C2C12 cells. NK4 treat-
ment enhanced ALP production in BMP-2-stimulated C2C12 cells
after 7 days of culture (Fig. 1A). Osteocalcin is a late osteoblast dif-
ferentiation marker [22]. We examined the effect of NK4 treatment
on osteocalcin production by the cells. NK4 treatment enhanced
osteocalcin production in BMP-2-stimulated C2C12 cells after
10 days of culture (Fig. 1C). To conﬁrm the effects of c-Met
signaling on osteoblast differentiation, we next examined the
Fig. 1. The hepatocyte growth factor (HGF) antagonist, NK4, and the c-Met inhibitor, SU11274, enhance osteoblast differentiation by C2C12 cells. C2C12 cells were treated
with bone morphogenetic protein (BMP)-2 (300 ng/mL) with or without either NK4 (100–300 nM; Fig. 1A, C) or SU11274 (0.25–2.5 lM; Fig. 1B, D) at a density of 1  105/mL/
well and cultured for either 7 or 10 days. ALP production by the cells was determined after 7 days culture (Fig. 1A, B) and osteocalcin production by the cells was determined
after 10 days culture (Fig. 1C, D). Runx2 mRNA expression was determined by using quantitative reverse transcription-polymerase chain reaction (RT-PCR). C2C12 cells were
seeded in 24-well tissue culture plates at a density of 1  106 cells/mL/well. The cells were stimulated with BMP-2 (300 ng/mL) with or without c-Met inhibitor. After 24 h of
culture, RNA was extracted and quantitative RT-PCR was performed (Fig. 1E). Data represent relative expression of Runx2 mRNA to b-actin mRNA (control). Data are
presented as mean ± standard error (SE; n = 3) for each experimental group. ⁄p < 0.05 vs. BMP-2 treatment.
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bitor (SU11274) signiﬁcantly enhanced both ALP and osteocalcin
production in BMP-2-stimulated C2C12 cells (Fig. 1B, D). Runx2
is an osteoblast-speciﬁc transcription factor, which is essential
for the differentiation of osteoblasts from mesenchymal precursors
[23,24]. Therefore, we examined whether Runx2 expression in
BMP-2-stimulated C2C12 cells was enhanced upon treatment with
c-Met inhibitor. We examined the mRNA expression levels of
Runx2 in BMP-2-stimulated C2C12 cells in the presence or absence
of c-Met inhibitor (SU11274). After 24 h of culture in the presence
of c-Met inhibitor, Runx2 mRNA levels were enhanced in
BMP-2-stimulated C2C12 cells (Fig. 1E). These results indicate that
blocking c-Met signaling in C2C12 cells enhances osteoblast
differentiation.
3.2. Blocking c-Met signal suppresses HGF production by C2C12 cells
C2C12 cells produce HGF, which in turn suppresses osteoblast
differentiation. This indicates that HGF negatively regulates osteo-
blast differentiation [13,14]. We next examined the effect of block-
ing c-Met signaling on HGF production by C2C12 cells. C2C12 cells
produced signiﬁcant amounts of HGF, and BMP-2 treatment
enhanced HGF production by C2C12 cells. Conversely, both NK4
(Fig. 2A) and SU11274 (Fig. 2B) suppressed HGF production by
C2C12 cells. These results indicate that blocking c-Met signaling
suppresses HGF production.3.3. c-Met inhibitor (SU11274) enhances ALP and osteocalcin
production in the pre-osteoblast cell line (MC3T3-E1 cells)
We next examined the effect of c-Met inhibitor on the pre-os-
teoblast cell line (MC3T3-E1 cells). c-Met inhibitor (SU11274) sig-
niﬁcantly enhanced both ALP and osteocalcin production in
osteoblast-inducer reagent-stimulated MC3T3-E1 cells (Fig. 3A, B).
3.4. SU11274 inhibits ERK1/2 and AKT phosphorylation by C2C12 cells
The MEK/ERK and PI3-AKT signaling pathways can be activated
by a variety of growth factors such as insulin and HGF [25–28]. To
determine whether ERK and AKT functioned downstream of the c-
Met signaling pathway, we examined the effects of SU11274 on
ERK1/2 and AKT phosphorylation in response to HGF treatment.
Stimulation of C2C12 cells with HGF led to a signiﬁcant increase
in the phosphorylation levels of ERK1/2 and AKT. Treatment with
c-Met inhibitor reduced HGF-mediated ERK1/2 and AKT phospho-
rylation (Fig. 4). These results indicate that the c-Met-MEK-ERK
and c-Met-PI3-AKT signaling pathways are active in C2C12 cells.
3.5. Effect of MEK 1/2 or PI3K inhibitor on osteoblast differentiation
We observed that blocking c-Met signaling enhanced ALP and
osteocalcin production by BMP-2-stimulated C2C12 cells (Fig. 1)
and that the c-Met-PI3-AKT and c-Met-MEK-ERK signaling
Fig. 2. Blocking c-Met signaling inhibits HGF production by C2C12 cells. C2C12 cells were treated with BMP-2 (300 ng/mL) with or without either NK4 (100–300 Nm; Fig. 2A)
or SU11274 (0.25–2.5 lM; Fig. 2B) at a density of 1  105/mL/well and cultured for 4 days. HGF production by the cells was determined. Data are presented as mean ± SE
(n = 3) for each experimental group. ⁄p < 0.05 vs. control treatment.
Fig. 3. c-Met inhibitor (SU11274) enhance ALP and osteocalcin production by the pre-osteoblast cell line (MC3T3-E1 cells). MC3T3-E1 cells were seeded in 24-well tissue
culture plates at a density of 1  105/mL/well. Cells were cultured with osteoblast- inducer reagent (OI; 2% b-glycerophosphate, 0.2% hydrocortisone, and 1% ascorbic acid-2-
phosphate) with or without c-Met inhibitor. ALP (Fig. 3A) or osteocalcin (Fig. 3B) activities in the culture supernatants were determined after 7 or 10 days of culture,
respectively. Data are presented as mean ± SE (n = 3) for each experimental group. ⁄p < 0.05 vs. control treatment.
Fig. 4. SU11274 inhibits ERK1/2 and AKT phosphorylation in C2C12 cells. C2C12
cells were treated with HGF (10 ng/mL) with or without SU11274 (2.5–250 nM) and
p-ERK1/2 and p-AKT expression was determined by Western blot analysis. b-Actin
expression was used as a control. Representative data for p-ERK1/2 and p-AKT
expression in C2C12 cells are shown.
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the effects of MEK1/2 inhibitor (PD98059) or PI3 K inhibitor
(Ly294002) on osteocalcin production by BMP-2-stimulated
C2C12 cells. In contrast to c-Met inhibitor, both PD98059 and
Ly294002 signiﬁcantly suppressed osteocalcin production by
C2C12 cells (Fig. 5A). PD98059 and Ly294002 also suppressed
HGF production by C2C12 cells (Fig. 5B). These results indicate that
blocking both c-Met signaling and other signaling pathways down-
stream of c-Met such as MEK-ERK and PI3-AKT suppresses HGF
production. However, blocking only the MEK-ERK and PI3-AKT
pathways suppressed osteoblast differentiation by C2C12 cells.
3.6. SU11274 inhibits Smad induction by C2C12 cells
The osteogenic activity of BMP-2 is partly mediated by nuclear
phosphorylation and nuclear translocation of Smads, which inter-
act directly with DNA and associate with other transcription fac-
tors to regulate osteogenesis [23,29]. Therefore, we investigated
whether blocking c-Met signaling enhanced osteoblast differentia-
tion by altering the phosphorylation status of Smads. Because the
PI3-AKT and MEK-ERK signaling pathways function downstream
of the c-Met signaling pathway in C2C12 cells, we also examined
the effect of MEK1/2 inhibitor (PD98059) or PI3 K inhibitor
Fig. 5. Effect of mitogen-activated protein kinase (MAPK)/ERK kinase (MEK) 1/2 or PI3 K inhibitor on osteoblast differentiation and p-Smads induction. C2C12 cells were
treated with BMP-2 (300 ng/mL) with or without either PD98059 (60 lM) or Ly294002 (60 lM) at a density of 1  105/mL/well and cultured for 10 days. Osteocalcin (Fig. 5A)
or HGF (Fig. 5B) production by the cells was determined. Data are presented as mean ± SE (n = 3) for each experimental group. ⁄p < 0.05 vs. BMP-2 treatment. C2C12 cells were
treated with BMP-2 (300 ng/mL) with or without either SU11274 (250 nM), PD98059 (60 lM), or Ly294002 (60 lM) for 10 min and p-Smad1/5/8 expression was determined
by Western blot analysis. Representative data for p-Smad1/5/8 and b-actin expression by C2C12 cells (Fig. 5C). Relative p-Smad1/5/8 expression (p-Smad1/5/8/b-actin;
Fig. 5D).
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enhanced Smad phosphorylation in C2C12 cells. SU11274 inhibited
BMP-2-stimulated Smad phosphorylation in C2C12 cells. In addi-
tion, both PD98059 and Ly294002 signiﬁcantly inhibited BMP-2-
stimulated Smad phosphorylation in C2C12 cells (Fig. 5C, D).
Taken together these results indicate that the c-Met-PI3-AKT-
Smad and c-Met-MEK-ERK-Smad signaling pathways positively
regulate osteoblast differentiation. However, independent of the
MEK-ERK-Smad and PI3 K-AKT-Smad pathways, c-Met signaling
negatively regulates osteoblast differentiation.
4. Discussion
We previously reported that the HGF antagonist, NK4, inhibited
arthritis and bone destruction by inhibiting angiogenesis and
inﬂammatory cell inﬁltration in the synovium in SKG mice [15].
In this study, we demonstrated that blocking c-Met signaling
induces bone formation by enhancing osteoblast differentiation
in C2C12 myoblasts. Blocking c-Met signaling by HGF antagonist
(NK4) or c-Met inhibitor (SU11274) enhanced osteocalcin produc-
tion by C2C12 cells stimulated with BMP-2 (Fig. 1). C2C12 cells
spontaneously produced signiﬁcant amounts of HGF, which inhib-
ited BMP-induced osteoblast differentiation [13,14]. Although
BMP-2 stimulation enhanced HGF production, both NK4 andSU11274 inhibited BMP-2-induced HGF production by C2C12 cells
(Fig. 2). These results suggest that both NK4 and SU11274 directly
block c-Met signaling not only by binding to its receptors but also
by suppressing HGF production, which negatively regulates osteo-
blast differentiation by C2C12 cells.
To conﬁrm that both ERK1/2 and AKT are downstream signal
molecules of c-Met we examined the phosphorylation status of
these molecules after stimulation with HGF. Inhibition of c-Met
signaling using c-Met inhibitor suppressed both ERK1/2 and AKT
phosphorylation by HGF-stimulated C2C12 cells, suggesting that
the c-Met-MEK-ERK and c-Met-PI3K-AKT signaling pathways are
active in C2C12 cells (Fig. 4). However, in contrast to c-Met inhibi-
tor, inhibitors of both MEK1 and PI3K suppressed osteocalcin pro-
duction in BMP-2-stimulated C2C12 cells (Fig. 5A). These results
suggest that the c-Met-MEK-ERK and c-Met-PI3K-AKT pathways
positively regulate osteoblast differentiation, but c-Met signaling
negatively regulates osteoblast differentiation, independent of
the MEK-ERK and PI3K-AKT pathways.
BMP receptors are serine/threonine kinase receptors and they
may be classiﬁed into two types: I (BMPR-I) and II (BMPR-II).
After BMP binding, BMPR-I kinases are activated by BMPR-II
kinase-induced phosphorylation. Smad proteins are then required
to activate the receptors. Therefore, Smads play a role in transmit-
ting the BMP signal from the receptor to the target gene [23,29]. In
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pressed BMP-2-induced Smad phosphorylation in C2C12 cells, sug-
gesting that the c-Met-MEK-ERK and c-Met-PI3K-AKT signaling
pathways positively regulate BMP-2-induced Smad phosphoryla-
tion (Fig. 5C, D).
In addition to the activation of Smads, BMP-2 activates non-
Smad signaling molecules, including members of the MAPK family
such as p38, ERK1/2, and JNK [30–32]. Furthermore, it was demon-
strated that PI3K and its downstream target, AKT, are required for
the BMP-2-induced expression of an osteoblast differentiationmar-
ker, alkaline phosphatase, and for BMP-2 transcription [33,34].
Therefore, BMP-2-induced MEK-ERK and PI3K-AKT signaling
pathwaysmay also induce osteoblast differentiation by C2C12 cells,
independent of the Smad signaling pathways. Our results indicate
that although both c-Met-MEK-ERK-Smad and c-Met-PI3K-AKT-
Smad signals enhance osteoblast differentiation, c-Met signaling,
independent of MEK-ERK-Smad and PI3K-AKT-Smad signaling,
strongly suppresses osteoblast differentiation in C2C12 cells.
Several studies have demonstrated that c-Met signaling stimu-
lates osteoblastic differentiation in several cell types. Aenlle et al.
demonstrated that HGF promote osteoblast differentiation by
inducing rapid phosphorylation of p38 using human mesenchymal
stem cells [35]. Chen et al. demonstrated that HGF in combination
with a known inducer of osteogenic differentiation, 1,25-dihydrox-
yvitamin D, signiﬁcantly increased osteoblast differentiation in
human bone marrow-derived stem cells [36]. However, our studies
suggest that the HGF antagonist promotes osteoblast differentia-
tion. Why these studies yielded contradictory results in different
cell types is not clear. One reason for this discrepancy may be
the different cell sources that were used in the studies. We used
murine cell line such as C2C12 and MC3T3-E1, while Aenlle et al.
and Chen et al. used human cells in their experiments. Another
possible reason is the difference in the timing of HGF treatment.
Kawasaki et al. reported that treatment with HGF during BMP-2-
induced osteoblast differentiation enhanced osteoblast differentia-
tion. In contrast, they also demonstrated that treatment of HGF
prior to BMP-2 induced cellular proliferation did not inﬂuence sub-
sequent osteoblast differentiation [14].
To our knowledge, this is the ﬁrst study to demonstrate that
blocking c-Met signaling enhances osteoblast differentiation, inde-
pendent of the MEK-ERK-Smad and PI3K-AKT-Smad signaling
pathways. Severe articular destruction in RA patients is caused
not only by synovial cell proliferation (the synovial cells invade
articular bone) but also by severe local osteoporosis due to inﬂam-
matory reactions. Therefore, Inhibition of c-Met signaling might be
a useful therapeutic strategy for the treatment of RA by enhancing
osteoblast differentiation in patients with RA.
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